Merck Sharpe and Dohme reports findings from CINV drug trial
3 June 2010 00:00 in Pharmaceutical Company Product News
Merck Sharpe and Dohme has announced the results from a clinical trial of a new drug regimen for the treatment and prevention of chemotherapy-induced nausea and vomiting (CINV).
The company conducted a phase III study comparing an investigational combination of fosaprepitant dimeglumine, a 5-HT3 antagonist and dexamethasone to a similar regime based on aprepitant.
It was found that Merck Sharpe and Dohme's treatment option delivered non-inferior performance among patients receiving a first cycle of cisplatin-based chemotherapy.
Dr Steven Grunberg, professor of medicine and Pharmacology at the University of Vermont, expressed hope that these findings will lead to the development of a new formulation of the aprepitant-based treatment Emend.
He added: "These findings are important because prevention of CINV is a major concern and this formulation of Emend could potentially provide dosing flexibility to prevent CINV."
Last month, Merck Sharpe and Dohme published new trial data which demonstrated the effectiveness of its atrial fibrillation treatment Brinavess compared to an amiodarone injection.
Other news stories from 03/06/2010
Related news
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency
